Menu
Search
|

Menu

Close
X

Radius Health Inc RDUS.OQ (NASDAQ Stock Exchange Global Market)

18.95 USD
-0.26 (-1.35%)
As of 3:15 PM BST
chart
Previous Close 19.21
Open 19.17
Volume 10,008
3m Avg Volume 264,980
Today’s High 19.32
Today’s Low 18.80
52 Week High 41.14
52 Week Low 16.71
Shares Outstanding (mil) 43.50
Market Capitalization (mil) 1,686.22
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.25 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
37
FY17
22
FY16
0
FY15
0
EPS (USD)
FY18
-2.886
FY17
-5.802
FY16
-4.244
FY15
-2.533
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
1,720.64
5.74
Price to Book (MRQ)
vs sector
8.13
5.00
Price to Cash Flow (TTM)
vs sector
--
23.28
Total Debt to Equity (MRQ)
vs sector
0.00
16.89
LT Debt to Equity (MRQ)
vs sector
0.00
12.55
Return on Investment (TTM)
vs sector
-75.07
14.60
Return on Equity (TTM)
vs sector
-75.11
16.33

EXECUTIVE LEADERSHIP

Kurt Graves
Independent Chairman of the Board, Since 2011
Salary: --
Bonus: --
Jesper Hoiland
President, Chief Executive Officer, Director, Since 2017
Salary: $275,000.00
Bonus: $206,250.00
Jose Carmona
Chief Financial Officer, Senior Vice President, Treasurer, Since 2017
Salary: $261,835.00
Bonus: $104,734.00
Gary Hattersley
Senior Vice President, Chief Scientific Officer, Since 2014
Salary: $395,000.00
Bonus: $158,000.00
Brent Hatzis-Schoch
Senior Vice President, General Counsel, Secretary, Since 2017
Salary: $405,000.00
Bonus: $162,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

950 Winter St
WALTHAM   MA   02451-1424

Phone: +1617.5514000

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

SPONSORED STORIES